

DAFTAR PUSTAKA

1. Terracciano E, Amadori F, Zaratti L, Franco E. [Tuberculosis: an ever present disease but difficult to prevent]. *Ig Sanita Pubbl.* 2020;76(1):59–66.
2. Mbuh TP, Ane-Anyangwe I, Adeline W, Thumamo Pokam BD, Meriki HD, Mbacham WF. Bacteriologically confirmed extra pulmonary tuberculosis and treatment outcome of patients consulted and treated under program conditions in the littoral region of Cameroon. *BMC Pulm Med.* 2019 Jan;19(1):17.
3. WHO. 2024 Global tuberculosis report [Internet]. 2024. p. 69. Available from: <https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024>
4. Kementerian Kesehatan RI. Laporan Program Penanggulangan Tuberkulosis Tahun 2023 [Internet]. Kemenkes RI. Kementerian Kesehatan RI; 2024. 1–156 p. Available from: https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/
5. Jacobo-Delgado YM, Rodríguez-Carlos A, Serrano CJ, Rivas-Santiago B. Mycobacterium tuberculosis cell-wall and antimicrobial peptides: a mission impossible? *Front Immunol.* 2023;14:1194923.
6. Alsayed SSR, Gunosewoyo H. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. *Int J Mol Sci* [Internet]. 2023;24(6). Available from: <https://www.mdpi.com/1422-0067/24/6/5202>
7. PDPI. Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia [Internet]. Vol. 001, Perhimpunan Dokter Paru Indonesia. 2021. 1–78 p. Available from: <https://bukupdpi.klikpdpi.com/wp-content/uploads/2022/08/BUKU-GUIDELINE-TB-2021.pdf>
8. Soedarsono S, Riadi ARW. Tuberculosis drug-induced liver injury. *J Respirasi.* 2020;6(2):49–54.
9. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. *Drug Saf.* 2001;24(7):483–90.
10. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. *J Hepatol* [Internet]. 2023;79(2):516–37. Available from: <https://www.sciencedirect.com/science/article/pii/S0168827823001940>
11. Soedarsono S, Mandayani S, Prayuni K, Yuliwulandari R. the Risk Factors for Drug Induced Hepatitis in Pulmonary Tuberculosis Patients in Dr. Soetomo Hospital. *Indones J Trop Infect Dis.* 2018;7(3):73.

12. Naqvi IH, Mahmood K, Talib A, Mahmood A. Antituberculosis Drug-Induced Liver Injury: An Ignored Fact, Assessment of Frequency, Patterns, Severity and Risk Factors. *Open J Gastroenterol*. 2015;05(12):173–84.
13. Gaude G, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. *J Fam Med Prim Care*. 2015;4(2):238.
14. Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *J Clin Exp Hepatol* [Internet]. 2013;3(1):37–49. Available from: <http://dx.doi.org/10.1016/j.jceh.2012.12.001>
15. Freire ID, Fielding KL, Moore DAJ. Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment? *PLoS One* [Internet]. 2023;18(5 May):1–14. Available from: <http://dx.doi.org/10.1371/journal.pone.0286306>
16. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi BU, Salkeen S. Hepatotoxicity with antituberculosis drugs: The risk factors. *Pakistan J Med Sci*. 2007;23(1):33–8.
17. Zhong T, Fan Y, Dong XL, Guo X, Wong KH, Wong WT, et al. An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis. *Front Pharmacol*. 2021;12(November):1–9.
18. Gopalakrishna H, Chalasani N. Drug-induced liver injury due to first-line antituberculosis medications in India: A major hindrance to achieve the goal of tuberculosis elimination. *Indian J Gastroenterol* [Internet]. 2024;(0123456789). Available from: <https://doi.org/10.1007/s12664-024-01674-3>
19. Geng X, Wu X, Yang Q, Xin H, Zhang B, Wang D, et al. Whole transcriptome sequencing reveals neutrophils' transcriptional landscape associated with active tuberculosis. *Front Immunol*. 2022;13.
20. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, et al. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. *Lancet Infect Dis*. 2018 Mar;18(3):e64–75.
21. Moule MG, Cirillo JD. Mycobacterium tuberculosis Dissemination Plays a Critical Role in Pathogenesis. *Front Cell Infect Microbiol*. 2020;10:65.
22. Carabalí-Isajar ML, Rodríguez-Bejarano OH, Amado T, Patarroyo MA, Izquierdo MA, Lutz JR, et al. Clinical manifestations and immune response to tuberculosis. *World J Microbiol Biotechnol* [Internet]. 2023;39(8):206. Available from: <https://doi.org/10.1007/s11274-023-03636-x>
23. European Centre for Disease Control. Handbook on tuberculosis laboratory

- diagnostic methods in the European Union [Internet]. Technical Report. 2018. 50–59 p. Available from: www.ecdc.europa.eu
24. Rekha B, Dushyant Singh G, Aarti K, Anuradha K. Comparison of Ziehl - Neelsen (ZN) Staining and Fluorescent (FL) Staining in Suspected Cases of Tuberculosis. *Int J Pathol Clin Res*. 2021;7(1).
 25. Huang Y, Ai L, Wang X, Sun Z, Wang F. Review and Updates on the Diagnosis of Tuberculosis. *J Clin Med*. 2022;11(19).
 26. Peloquin CA, Davies GR. The Treatment of Tuberculosis. *Clin Pharmacol Ther*. 2021;110(6):1455–66.
 27. Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. *Nat Rev Dis Prim* [Internet]. 2019;5(1):58. Available from: <https://doi.org/10.1038/s41572-019-0105-0>
 28. Dipali D. Zade, Raut PA. Hepatotoxicity Induced by Anti-Tuberculosis Medications: Exploring Causes, Risk Factors, and Potential Mitigation Strategies Dipali. *J Drug Deliv Ther*. 2019;9(4):173–80.
 29. Garcia Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena M, Andrade R. Drug induced liver injury: an update. *Arch Toxicol*. 2020 Oct 1;94.
 30. Fisher K, Vuppalandhi R, Saxena R. Drug-Induced Liver Injury. *Arch Pathol Lab Med*. 2015 Jul;139(7):876–87.
 31. Yu Y cheng, Mao Y min, Chen C wei, Chen J jun, Chen J, Cong W ming, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. *Hepatol Int*. 2017;11(3):221–41.
 32. Jessica Raphaela Pranata, I Ketut Mariad, Gde Somayana. Prevalensi dan Gambaran Umum Drug-Induced Liver Injury Akibat Obat AntiTuberkulosis pada Pasien Tuberkulosis RSUP Sanglah Denpasar Periode Agustus 2016– Juli 2017. *J Med Udayana*. 2019;8.
 33. Chan R, Benet LZ. Evaluation of DILI Predictive Hypotheses in Early Drug Development. Vol. 30, *Chemical Research in Toxicology*. 2017. 1017–1029 p.
 34. Chalasani N, Björnsson E. Risk Factors for Idiosyncratic Drug-Induced Liver Injury. *Gastroenterology*. 2010;138(7):2246–59.
 35. Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, et al. Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. *J Antimicrob Chemother*. 2017;72(4):1172–7.
 36. Jong E, Conradie F, Berhanu R, Black A, John MA, Meintjes G, et al. Guideline: Consensus statement: Management of drug-induced liver injury in HIV-positive

- patients treated for TB. *South Afr J HIV Med.* 2013;14(3):113–9.
37. Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. *J Hepatol.* 2019;70(6):1222–61.
 38. Banjuradja I, Singh G. Mekanisme hepatotoksitas dalam tatalaksana tuberkulosis pada gangguan hati. *Indones J Chest |.* 2020;7(2):55–64.
 39. Rahman MM, Setyawati T, Sarifuddin, Wahyuni RD. Mekanisme OAT dalam tubuh yang mengakibatkan risiko DILI (drug-induced liver injury): literature review. *J Med Prof.* 2023;5(1):41–7.
 40. Huang D, Dai W, Chen J, Ye X. Clinical features of liver injury induced by anti - Tuberculosis drugs and related risk factors. *J Clin Hepatol.* 2021;37(10):2369–75.
 41. Amacher DE. Female gender as a susceptibility factor for drug-induced liver injury. *Hum Exp Toxicol.* 2014;33(9):928–39.
 42. Lim J, Kim JS, Kim HW, Kim YH, Jung SS, Kim JW, et al. Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea. *Open forum Infect Dis.* 2023 Aug;10(8):ofad422.
 43. Naidoo S, Evans D, Jong E, Mellet K, Berhanu R. Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury. *S Afr Med J.* 2015 Apr;105(5):393–6.
 44. Zhang F, Zhang F, Qin M, Li L. Alcohol consumption as a risk factor for anti-tuberculosis drug induced liver injury: A systematic review and meta-analysis. *Microb Pathog.* 2024 Nov;196:107003.
 45. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. *Gastroenterology.* 2014 Jul;147(1):96–108.e4.
 46. Munawarah, Djide MN, Santoso A, Wahyuddin E, Sartini, Djabir YY. Pengaruh Penggunaan Sediaan Fixed Dose Combination (FDC) Dibandingkan Dengan Tablet Lepas Obat Anti-Tuberkulosis Terhadap Peningkatan Nilai SGPT Dan SGOT Pada Pasien Tuberkulosis Di Balai Besar Kesehatan Paru Masyarakat Makassar. *Maj Farm dan Farmakol.* 2019 Apr;23(1):32–4.
 47. Weersink RA, Alvarez-Alvarez I, Medina-Cáliz I, Sanabria-Cabrera J, Robles-Díaz M, Ortega-Alonso A, et al. Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. *Clin Pharmacol Ther.* 2021;109(4):1147–58.

48. Shakya R, Rao BS, Shrestha B. Evaluation of Risk Factors for Antituberculosis Drugs-Induced Hepatotoxicity in Nepalese. *Kathmandu Univ J Sci Eng Technol*. 2006;2(1):1–8.
49. Jiang F, Yan H, Liang L, Du J, Jin S, Yang S, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. *Liver Int*. 2021;41.
50. Liu Q, Huang L, Yan H, Zong Z, Chen Z, Wu X, et al. Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury. *Front Pharmacol*. 2024;15:1406454.
51. Schutz C, Ismail Z, Proxenos CJ, Marais S, Burton R, Kenyon C, et al. Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. *S Afr Med J*. 2012 Mar;102(6):506–11.
52. Devarbhavi H, Joseph T, Sunil Kumar N, Rathi C, Thomas V, Prasad Singh S, et al. The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients. *J Clin Exp Hepatol*. 2021;11(3):288–98.
53. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WCM, van der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. *J Gastroenterol Hepatol*. 2008 Feb;23(2):192–202.
54. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. *Hepatology*. 2016 Feb;63(2):590–603.
55. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: a critical review. *Br J Clin Pharmacol*. 2013 Mar;75(3):630–6.
56. Al-Shaer MH, Mansour H, Elewa H, Salameh P, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. *BMC Infect Dis*. 2017 Feb;17(1):118.